Cytori Receives Positive European Opinion on Scleroderma Orphan Drug Status
Cytori Therapeutics, Inc. recently announced that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has given a positive opinion concerning Cytori’s submission for an orphan drug designation for ECCS-50, the company’s experimental Scleroderma therapeutic, which is based on stromal vascular fraction cells, from adipose tissue and derived from Celution® System,…